Journal of Clinical Oncology

Papers
(The H4-Index of Journal of Clinical Oncology is 137. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.1448
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.991
Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.933
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.696
Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.676
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.612
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.597
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.586
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non–small-cell lung cancer (NSCLC) refractory to first-line o557
A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.538
Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population.520
Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.470
Representativeness of patients with lung cancer in an integrated health care delivery system.455
The molecular signature of gain-of-function (GOF) vs. non-GOF classification TP53 mutations in colorectal cancer.437
Burnout in oncology nurses.429
Reevaluating the role of adjuvant chemotherapy in early-stage, resectable NSCLC with high-risk clinical and pathologic features.411
Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.391
Redefining early-onset cancer and risk of hereditary cancer predisposition.380
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.369
Single cell multiomic profiling of high-grade serous carcinoma.353
Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.350
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).345
Early integration of exercise into breast cancer care: The MSK healthy living program.340
ctDNA-based genomic landscape analysis to evaluate molecular brake and gatekeeper mutations in FGFR2 alterations.336
Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.336
Impact of economic inequality on Kaposi sarcoma of the lung: A retrospective cohort.335
Information and decisional needs of patients (pts) with newly diagnosed advanced cancer in the hospital: A multi-level, mixed-methods study.334
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.323
Cascade genetic testing (CGT) female first-degree relatives (FDR) of men with germline BRCA2 mutations (gBRCA2mut) and prostate cancer (PCa): A cost-effectiveness analysis.319
Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.315
Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.301
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.293
Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network.290
Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).288
Multi-omics study of the genomic features and clinical characteristics of hepatic sarcomatoid carcinoma located at different sites.282
Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma.279
Body image disturbances in adolescent and young adult patients with cancer confronting infertility risk and fertility preservation decisions.277
Sun exposure and associated risks: Insight from an international survey with a focus on the organ transplant recipient population.270
Is Medicare Advantage associated with more favorable health care access, acute care utilization, and affordability among beneficiaries with cancer?266
Enhancing patient clinical streamlining (EPACS) pilot in the breast medicine service at memorial sloan kettering cancer center.263
Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patie260
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NS256
Hearing loss related outcomes post-lateral temporal bone resection and other oncologic treatment.254
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controll250
Arterial chemotherapy in advanced hepatocellular carcinoma: An evolutionary trajectory exploration and pooled outcome analysis.246
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.246
Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.240
The impact of using Elsevier ClinicalPath oncology treatment pathways on survival and cost of care.237
Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: A prospective study.233
Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.232
Predicting therapy-induced cardiomyopathy in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).230
A national survey of current scenario and future perspectives of cancer research in Brazil.226
Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001).225
The five periampullary cancers: Not just different siblings but different families—An international multicenter cohort study.224
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.221
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.221
Impact of SARS-COV2 infection on the clinical outcomes in patients with lung cancer compared to all other cancers.220
Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05).219
The efficacy and safety of anlotinib combined with bevacizumab in treatment of recurrent isocitrate dehydrogenase wildtype glioblastoma: A retrospective analysis.219
Outcomes of Helicobacter pylori (HP) infection in esophageal cancer (EC): A 5-year nationwide analysis.217
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.216
Ten-year outcomes of hypofractionated (45 Gy in 9 fractions) intensity-modulated radiotherapy for localized prostate cancer.215
Surgery with adjuvant chemotherapy versus chemoradiation for early-stage large cell neuroendocrine cancer (LCNEC) of the lung: A SEER plus based analysis.214
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuva214
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.214
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx stud213
Subsequent meningiomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).212
3D genomics identifies previously unreported yet clinically actionable gene fusions and complex rearrangements in a cohort of driver-negative colorectal carcinoma tumors.211
Positive margin and advanced depth of invasion as the indicators for assessing the necessity of adjuvant chemoradiotherapy in early-stage oral cavity squamous cell carcinoma.205
Clinicopathologic features and outcomes associated with induction regimen intensity among older veterans with myeloma.204
ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer.202
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.201
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.201
A study on oligo-progression after durvalumab plus platinum-etoposide for ES-SCLC.200
Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.200
Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).197
Concurrent EGFR wild-type tongue squamous cell carcinoma and EGFR-mutant lung adenocarcinoma and response to osimertinib.197
Clinical and molecular Characterization of NSCLCs with MET exon 14 skipping mutation coexist MET amplification.196
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.195
Racial and income characteristics and the burden of illness among metastatic prostate cancer patients.194
Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.193
Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC.192
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.191
Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer.188
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.181
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing granulocytopenia in sarcoma patients receiving doxorubicin combined with ifosfamide: A prospective, randomized, non-inferiority phase II180
Healthcare utilization among individuals diagnosed with hereditary breast-ovarian cancer syndrome through a universal germline genetic testing program.179
The Ohio State University Guardant Shield Colorectal Cancer Screening Project.177
Association of patient and tumor characteristics with outcomes in young patients with head and neck squamous cell carcinoma (HNSCC).177
A national analysis evaluating the role of neoadjuvant chemoradiotherapy in upper esophageal cancer.174
Donafenib combined with anti-PD-1 antibody as adjuvant treatment in patients with hepatocellular carcinoma at high risk of recurrence after radical resection: A retrospective analysis.173
Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal ca171
Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A r170
Artificial neural network model analysis in T790M detection after failure of first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.169
The impact of COVID-19 on anxiety among breast cancer survivors before, during and after the pandemic.168
Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.167
Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue.166
Relationship between androgen biosynthesis linked to 3βHSD1 and resistance to radiotherapy: A germline biomarker for combined androgen blockade with radiation in high-risk prostate cancer.165
Patterns of diversity in cancer clinical trial enrollment at a New York City academic health system, 2018-2022.164
UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.163
Mobile-based multimodal rehabilitation including exercise, nutritional, and psychological interventions in patients with abdominal cancer receiving concurrent chemoradiotherapy: Prospective, multicent163
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.162
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).162
Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.159
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.159
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.158
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The immunowave study.157
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.157
Pegylated liposomal doxorubicin combined with ifosfamide for advanced soft tissue sarcomas: A phase I dose-escalation study.156
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.156
Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network.154
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.153
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.153
Beyond gemtuzumab ozogamicin: A systematic review of antibody therapies for acute myeloid leukemia.152
Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer and borderline pancreatic inoperabl151
Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.150
Scenery of multilocus inherited neoplasia alleles syndrome (MINAS) in a single Brazilian institution.149
The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients.148
Clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma.147
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.147
Mutational profiles of sporadic synchronous colorectal cancer.147
A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regi146
A cross sectional study on female sexual function following pelvic radiotherapy.145
Pan-Cancer analysis of the mutation frequency of genes in DDR pathway in Chinese population.145
Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.145
Improving goal concordant care clinician workshops: Do patients benefit?144
Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study.144
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.143
Hereditary cancer screening at an urban safety net hospital.142
Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.140
Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.140
Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC).140
Participation in cancer research in BNSSG, England: A Health Equity Audit 2021.140
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.139
Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC).139
Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape.138
Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.137
0.11098790168762